SEC Tracker
Get the app

Xilio Therapeutics XLO

Xilio Therapeutics Q3 FY23: net loss $16.7M; diluted EPS −$0.61

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.3
Material contract

Key figures from this report

These are the numbers Xilio Therapeutics reported for Q3 FY23, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$16.7MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$0.61No year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$59.8MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  4. Cash from operations−$13.4MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Xilio Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Grace Therapeutics GRCE public float $35M, Sep 30, 2025
  2. Annovis Bio ANVS public float $36M, Jun 30, 2025
  3. Kezar Life Sciences KZR public float $33M, Jun 30, 2025
  4. Abvc Biopharma ABVC public float $37M, Jun 30, 2025
  5. Karyopharm Therapeutics KPTI public float $37M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.